*** PRESS RELEASE*** Acumen® eX3 speeds up cytotoxicity profiling
TTP LabTech combines microplate cytometer with Invitrogen reagents
to maximise HCS parameters
Royston, GB, 15 May 2009 – TTP LabTech has today announced a number of high throughput platform solutions for the study of cytotoxicity. The platforms utilise the successful Acumen® eX3 fluorescence microplate cytometer and a number of new solutions for toxicity profiling developed by Invitrogen, a division of Life Technologies Corporation. This announcement comes at a time when such cellular based assays are being increasingly recommended as the first approach in determining drug on- and off- target effects.
The Acumen® eX3 laser scanning cytometer is an ultra-high throughput system for cell-based screening that offers enhanced multiplexing capability to maximise data content and the rapid generation of robust data sets when deployed with ready-to-use Molecular Probes® kits and reagents from Invitrogen. With these robust Molecular Probes® high-content screening products, a number of cytotoxic phenomena can be analysed including: cell viability, DNA damage and cell cycle processes such as mitosis. The strength of the Acumen® eX3 platform combined with these robust Invitrogen high content screening (HCS) products enables the high-throughput analysis of a wide variety of toxicity parameters.
Dr Paul Wylie, Acumen Product Manager, TTP LabTech, commented “The synergies between TTP LabTech’s analysis technologies and Invitrogen’s HCS reagents are fully exploited by these developments through the partnering of Acumen® eX3’s class-leading multiplexing performance with novel reagents of broad applicability”.